OraSure Technologies - OSUR Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $6.63
  • Forecasted Upside: 36.60%
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$4.85
▼ -0.07 (-1.42%)

This chart shows the closing price for OSUR by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New OraSure Technologies Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for OSUR and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for OSUR

Analyst Price Target is $6.63
▲ +36.60% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for OraSure Technologies in the last 3 months. The average price target is $6.63, with a high forecast of $9.00 and a low forecast of $5.00. The average price target represents a 36.60% upside from the last price of $4.85.

This chart shows the closing price for OSUR for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 3 investment analysts is to hold stock in OraSure Technologies. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
12/4/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
3/4/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
6/2/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
8/31/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
11/29/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
2/27/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
4/27/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
5/27/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/13/2024JPMorgan Chase & Co.Lower TargetNeutral ➝ Neutral$7.00 ➝ $6.00Low
4/4/2024Evercore ISILower TargetIn-Line ➝ In-Line$7.00 ➝ $6.50Low
12/11/2023CitigroupBoost TargetBuy ➝ Buy$7.00 ➝ $9.00Low
11/8/2023JPMorgan Chase & Co.Lower TargetNeutral ➝ Neutral$6.00 ➝ $5.00Low
7/17/2023StephensLower Target$6.50 ➝ $5.00Low
1/3/2023Evercore ISIInitiated Coverage$5.00Low
5/11/2022CitigroupLower Target$12.00 ➝ $10.00High
2/24/2022CitigroupLower TargetBuy$15.00 ➝ $12.00High
1/6/2022Lake Street CapitalLower TargetBuy ➝ Buy$20.00 ➝ $14.00High
9/22/2021Raymond JamesDowngradeOutperform ➝ Market PerformHigh
9/20/2021Lake Street CapitalBoost TargetBuy$15.00 ➝ $20.00Medium
8/4/2021Raymond JamesBoost TargetOutperform$11.00 ➝ $12.50High
8/4/2021Lake Street CapitalLower TargetBuy$20.00 ➝ $15.00High
8/4/2021CitigroupBoost TargetBuy$13.00 ➝ $15.00High
6/28/2021Raymond JamesLower TargetOutperform$12.00 ➝ $11.00High
5/6/2021Lake Street CapitalLower TargetBuy$24.00 ➝ $20.00High
5/6/2021Raymond JamesLower TargetOutperform$16.00 ➝ $12.00High
3/2/2021CitigroupLower Target$18.00 ➝ $16.00Medium
8/21/2020Evercore ISIInitiated CoverageOutperform$22.00High
8/10/2020CitigroupInitiated CoverageBuy$18.00Medium
8/10/2020JPMorgan Chase & Co.Initiated CoverageNeutral$18.00Medium
8/7/2020Raymond JamesUpgradeMarket Perform ➝ Outperform$16.00High
6/25/2020Lake Street CapitalInitiated CoverageBuy$19.00High
4/21/2020StephensInitiated CoverageEqual Weight$14.00Medium
(Data available from 5/27/2019 forward)

News Sentiment Rating

0.73 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/30/2023
  • 1 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
11/29/2023
  • 3 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
12/29/2023
  • 2 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/28/2024
  • 6 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/27/2024
  • 6 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/28/2024
  • 3 very positive mentions
  • 6 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
4/27/2024
  • 6 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
5/27/2024

Current Sentiment

  • 6 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
OraSure Technologies logo
OraSure Technologies, Inc., together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company's products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D. saliva alcohol test. It also offers genomic products under the Oragene and ORAcollect brands for collecting genetic material from human saliva; Colli-Pee collection devices for the volumetric collection of void urine samples; and microbiome laboratory testing and analytical services. In addition, the company provides microbiome products, such as OMNIgene GUT for self-collecting microbial DNA from feces or stool samples for gut microbiome profiling; OMNIgene GUT DNA and RNA collection devices; and OMNIgene GUT Dx collection device for collection of human fecal samples and the stabilization of DNA from the bacterial community. Additionally, it provides other diagnostic products, such as immunoassays and other in vitro diagnostic tests. The company markets its products to clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, commercial and industrial entities, disease risk management, diagnostics, pharmaceutical, biotech, nutrition, companion animal, and environmental markets. OraSure Technologies, Inc. was incorporated in 2000 and is based in Bethlehem, Pennsylvania.
Read More

Today's Range

Now: $4.85
Low: $4.81
High: $4.92

50 Day Range

MA: $5.60
Low: $4.85
High: $6.80

52 Week Range

Now: $4.85
Low: $4.38
High: $8.45

Volume

538,500 shs

Average Volume

875,811 shs

Market Capitalization

$358.71 million

P/E Ratio

16.17

Dividend Yield

N/A

Beta

0.23

Frequently Asked Questions

What sell-side analysts currently cover shares of OraSure Technologies?

The following sell-side analysts have issued research reports on OraSure Technologies in the last year: Citigroup Inc., Evercore ISI, JPMorgan Chase & Co., Stephens, StockNews.com, and TheStreet.
View the latest analyst ratings for OSUR.

What is the current price target for OraSure Technologies?

4 Wall Street analysts have set twelve-month price targets for OraSure Technologies in the last year. Their average twelve-month price target is $6.63, suggesting a possible upside of 36.6%. Citigroup Inc. has the highest price target set, predicting OSUR will reach $9.00 in the next twelve months. Stephens has the lowest price target set, forecasting a price of $5.00 for OraSure Technologies in the next year.
View the latest price targets for OSUR.

What is the current consensus analyst rating for OraSure Technologies?

OraSure Technologies currently has 2 hold ratings and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in OSUR, but not buy more shares or sell existing shares.
View the latest ratings for OSUR.

What other companies compete with OraSure Technologies?

Other companies that are similar to OraSure Technologies include CryoLife, Atrion, Anika Therapeutics, Cerus and Utah Medical Products. Learn More about companies similar to OraSure Technologies.

How do I contact OraSure Technologies' investor relations team?

OraSure Technologies' physical mailing address is 220 EAST FIRST STREET, BETHLEHEM PA, 18015. The medical instruments supplier's listed phone number is (610) 882-1820 and its investor relations email address is [email protected]. The official website for OraSure Technologies is www.orasure.com. Learn More about contacing OraSure Technologies investor relations.